Starbucks (SBUX) PT Lowered to $128 at Barclays

Go back to Starbucks (SBUX) PT Lowered to $128 at Barclays

Starbucks (SBUX) Stock Up on Upgrade to Overweight at Stephens, Continued Labor Investments Seen as a Smart Move

November 1, 2021 7:41 AM EDT

Shares of Starbucks (NYSE: SBUX) are up over 1% in pre-open Monday after Stephens analyst James Rutherford upgraded to Overweight from Equal-Weight with a new price target of $130.00 per share (from the prior $118.00).

The upgrade is based on three major positives: 1) September U.S. & China comps accelerated. 2) "Bad" news is out. 3) Support... More

Starbucks (SBUX) PT Lowered to $117 at Morgan Stanley

October 29, 2021 8:44 AM EDT

Morgan Stanley analyst John Glass lowered the price target on Starbucks (NASDAQ: SBUX) to $117.00 (from $124.00) while maintaining a Equalweight rating.

The analyst commented, "SBUX is well known for investing ahead of the curve, but this round, which materially resets near term margin/EPS... More

Starbucks (SBUX) PT Lowered to $142 at Jefferies

October 29, 2021 8:08 AM EDT

Jefferies analyst Andy Barish lowered the price target on Starbucks (NASDAQ: SBUX) to $142.00 (from $145.00) while maintaining a Buy rating.

The analyst commented, "F4Q SSS below Cons given Delta/staffing issues, but not unsurprising in our view, and we think these comp headwinds are... More

Starbucks (SBUX) Stock Plummets on a Revenue Miss, Disappointing EPS Guidance Prompts Analyst to Downgrade to Hold

October 29, 2021 5:56 AM EDT

Starbucks (NASDAQ: SBUX) reported Q4 EPS of $1.00, $0.01 better than the analyst estimate of $0.99. Revenue for the quarter came in at $8.1 billion versus the consensus estimate of $8.21 billion.

Shares of the company are down 4.7% in pre-open as a result.

Our strong finish to fiscal 2021, including record performance in the fourth quarter, demonstrates the resilience of Starbucks and reinforces the value of the bold strategic moves we have taken over the past two years. Through it all, we have thoughtfully navigated a strong recovery with an eye towards our future, all guided by our... More